A Randomised Comparison Evaluating Changes in Bone Mineral Density in Advanced Prostate Cancer: Luteinising Hormone-releasing Hormone Agonists Versus Transdermal Oestradiol

BACKGROUND: Luteinising hormone-releasing hormone agonists (LHRHa), used as androgen deprivation therapy (ADT) in prostate cancer (PCa) management, reduce serum oestradiol as well as testosterone, causing bone mineral density (BMD) loss. Transdermal oestradiol is a potential alternative to LHRHa. OB...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Eur Urol
Main Authors: Langley, Ruth E., Kynaston, Howard G., Alhasso, Abdulla A., Duong, Trinh, Paez, Edgar M., Jovic, Gordana, Scrase, Christopher D., Robertson, Andrew, Cafferty, Fay, Welland, Andrew, Carpenter, Robin, Honeyfield, Lesley, Abel, Richard L., Stone, Michael, Parmar, Mahesh K.B., Abel, Paul D.
Formato: Artigo
Idioma:Inglês
Publicado: Elsevier Science 2016
Assuntos:
Platinum Priority – Prostate Cancer
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4854173/
https://ncbi.nlm.nih.gov/pubmed/26707868
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eururo.2015.11.030
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares